Glomerular disease workshop.
Recent observations regarding intrinsic glomerular cell biology, particularly in the podocyte, have provided exciting new insights into potential pathogenic mechanisms of human glomerular disease. Although both immune and nonimmune mechanisms of glomerular injury have been studied previously, experimental models of disease and recent techniques that provide tools for molecular profiling show great promise for identifying glomerular disease biomarkers. Despite these recent advances, additional work in both basic and clinical studies of glomerular disease is needed to advance the field. Standardization of animal models of distinct forms of glomerular disease would likely facilitate the search for biomarkers. Several factors limit current efforts to implement clinical trials of glomerular disease. Identification of disease biomarkers, development of disease-specific end points, and organization of collaborative clinical groups are critical for ultimately designing and implementing appropriately powered trials of glomerular disease.
Meyers
Catherine M
CM
Division of Kidney, Urologic and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD 20892, USA. cm420i@nih.gov
Geanacopoulos
Mark
M
Holzman
Lawrence B
LB
Salant
David J
DJ
D000818:Animals; D015415:Biomarkers / Q000032:analysis; D002986:Clinical Trials as Topic; D020022:Genetic Predisposition to Disease; D005919:Glomerular Filtration Rate; D005921:Glomerulonephritis / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*; D006801:Humans; D007678:Kidney Glomerulus / Q000166:cytology / Q000473:pathology*; D008967:Molecular Biology; D017410:Practice Guidelines as Topic; D011379:Prognosis; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index
D015415:Biomarkers